An advisory panel to the US Food and Drug Administration (FDA) has recommended approving a diet pill that was rejected two years ago because of concerns over its side effects. Qnexa (phentermine plus topiramate) is made by Vivus of Mountain View, California, which saw its share price soar 78% when the drug received the thumbs-up on 23 February.
展开▼
